Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer

BACKGROUND: At least 50% of triple negative breast cancer (TNBC) overexpress the epidermal growth factor receptor, EGFR, which paved the way for clinical trials investigating its blockade. Outcomes remained dismal stemming from mechanisms of resistance particularly the nuclear cycling of EGFR, which...

Descripción completa

Detalles Bibliográficos
Autores principales: McKnight, Brooke N., Kim, Seongho, Boerner, Julie L., Viola, Nerissa T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160960/
https://www.ncbi.nlm.nih.gov/pubmed/32295603
http://dx.doi.org/10.1186/s13058-020-01270-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160960/
https://www.ncbi.nlm.nih.gov/pubmed/32295603
http://dx.doi.org/10.1186/s13058-020-01270-1

Ejemplares similares